Tsuji Y, Ariyoshi A, Nakamura H, Michinaga S, Tomita Y, Ohmori A, Tahara H, Yamashita Y, Fujisawa Y, Kajiwara I
Department of Urology, Fukuoka University Chikushi Hospital.
Hinyokika Kiyo. 1992 Aug;38(8):961-6.
A multicenter trial was carried out on 100 patients with benign prostatic hypertrophy to elucidate the efficacy of anti-androgen therapy with allylestrenol (AE). AE was administered at a daily dose of 50 mg for 16 weeks to the patients and its efficacy was evaluated with subjective symptom scores, residual urine volume and uroflow rates. The effects of AE on prostatic volume and morphology were evaluated using transrectal ultrasound. Of these patients 65 completed the protocol, and only three patients withdrew from the study owing to side effects. Very modest adverse effects on sexual performance were seen in one patient. In this study, significant beneficial effects of AE on symptom scores, residual urine, maximum flow rate, and prostate size were demonstrated. However, volumetric reduction was not associated with urodynamic improvement. Prostatic shape was not changed throughout the study. These findings suggest that allylestrenol can be used as an alternative to prostatectomy in patients who are at high risk for surgery.
对100例良性前列腺增生患者进行了一项多中心试验，以阐明烯丙雌醇（AE）抗雄激素治疗的疗效。患者每日服用50 mg AE，持续16周，并通过主观症状评分、残余尿量和尿流率评估其疗效。使用经直肠超声评估AE对前列腺体积和形态的影响。这些患者中有65例完成了方案，只有3例患者因副作用退出研究。1例患者出现了对性功能非常轻微的不良反应。在本研究中，AE对症状评分、残余尿量、最大尿流率和前列腺大小有显著的有益影响。然而，体积缩小与尿动力学改善无关。在整个研究过程中前列腺形状未发生改变。这些发现表明，烯丙雌醇可作为手术高危患者前列腺切除术的替代方法。
